Sleep
Sleep Apnea and Longevity
Severe sleep apnea is associated with higher mortality. CPAP improves symptoms, but randomized trials have not shown cardiovascular-event prevention overall.
Sleep apnea is common, often undiagnosed and easy to wave off as “just snoring.” But the snoring is only the soundtrack. The real issue is that breathing can stop and restart over and over through the night, repeatedly dropping oxygen and nudging the brain awake. Severe obstructive sleep apnea is associated with cardiovascular disease and earlier death. Humanic Blue follows the less tidy part of the story: whether treatment changes those long-term outcomes.
Severe sleep apnea is linked to a higher risk of dying, but trials of CPAP have not shown an overall reduction in serious heart and blood-vessel problems. CPAP, short for continuous positive airway pressure, uses pressurized air to keep the airway open. It improves sleepiness and sleep-related quality of life. People who use it more consistently have had better heart-related outcomes in some analyses, but researchers did not randomly assign them to use it for longer. That leaves uncertainty about whether CPAP use itself explains the difference. The FDA also approved tirzepatide for moderate-to-severe apnea in adults with obesity. Whether either treatment helps people live longer remains unproven.
Key Takeaways
- Severe sleep-disordered breathing was associated with higher all-cause mortality in a large community cohort, with the clearest result in men ages 40 to 70. The study observed participants rather than assigning treatment.
- CPAP has not reduced cardiovascular events in randomized trials overall.
- Use of CPAP for at least four hours a night was associated with fewer repeat cardiovascular events, but adherence comparisons are not randomized.
- Positive-airway-pressure therapy improves excessive sleepiness and sleep-related quality of life.
How is untreated apnea linked to lifespan?
Obstructive sleep apnea means the airway repeatedly narrows or closes during sleep, cutting oxygen and waking the brain—even when you do not remember waking. Clinicians count those interruptions with the apnea-hypopnea index (AHI), which is simply the average number of breathing events per hour.
The Sleep Heart Health Study, published in 2009, used in-home sleep monitoring in adults age 40 and older and followed them over several years. Severe sleep-disordered breathing—at least 30 breathing events per hour—was associated with 46% higher all-cause mortality compared with fewer than five events per hour. The clearest subgroup result was in men ages 40 to 70, whose mortality was approximately doubled. Mild and moderate categories were not associated with statistically clear increases.
Measures of low nighttime oxygen, rather than sleep fragmentation, were independently associated with mortality. This does not prove the breathing disorder caused the deaths: treatment was not assigned, health conditions can influence both apnea and mortality, and subgroup findings need restraint. The lead author disclosed payments from two positive-airway-pressure (PAP) device makers, and another author held related patents.
How common apnea is after 50 is covered in Longevity Checklist for Your 50s.
What have apnea treatment trials found?
What SAVE tested. The SAVE trial, published in the New England Journal of Medicine in 2016, randomly assigned adults aged 45 to 75 with moderate-to-severe apnea and existing heart disease or stroke to CPAP plus usual care or usual care alone. Most were men with little daytime sleepiness.
Over a mean 3.7 years, CPAP did not significantly reduce the trial’s combined cardiovascular outcome. Average use was 3.3 hours a night, and the participants were mostly men with little daytime sleepiness, limiting how broadly the cardiovascular result applies. Within this trial, CPAP reduced snoring and sleepiness and modestly improved quality of life and mood.
Combining trials, then comparing use. A 2023 analysis combined three trials and found no overall reduction in repeat serious heart or brain blood-vessel problems. A separate comparison found fewer problems among people using CPAP for at least four hours a day. Researchers tried to account for differences between participants and changes in use, but did not randomly assign how long anyone used CPAP. Consistent users may differ in other ways that affect their health. Several authors disclosed grants or fees from ResMed.
A 2026 review of 11 randomized trials reached a similar overall result: no statistically clear reduction in major cardiovascular events or mortality. Its comparison of longer and shorter use also favored people using CPAP for at least four hours. But those groups were not randomly assigned, so the result cannot establish that four hours provides protection. Four hours is a research cutoff here, not a nightly treatment target.
How do symptoms, cardiovascular events and adherence lead to different readings of an apnea trial?
Which new option has FDA approval?
On December 20, 2024, the FDA approved tirzepatide (Zepbound) as the first medication indicated for moderate-to-severe obstructive sleep apnea in adults with obesity. The indication specifies use with a reduced-calorie diet and increased physical activity, according to the FDA announcement.
The approval rested on two 52-week SURMOUNT-OSA trials in adults with obesity, moderate-to-severe apnea and no type 2 diabetes. One trial enrolled people unable or unwilling to use positive airway pressure; the other enrolled people using it. Tirzepatide reduced breathing interruptions by about 20 to 24 more events per hour than placebo from starting averages near 50, while also producing substantial weight loss. The most frequent side effects involved the stomach and digestive system and were mostly mild to moderate. These Eli Lilly-funded trials were designed around apnea severity and related measures, not heart attacks, mortality or lifespan. The current FDA label lists circumstances in which the drug should not be used, important warnings and dose instructions that require clinician review.
Should you be screened?
The US Preventive Services Task Force found insufficient evidence to recommend for or against screening adults in the general population who do not have recognized symptoms. That statement is not advice to ignore loud snoring, gasping, witnessed pauses in breathing or excessive daytime sleepiness.
For adults with concerning symptoms, the American Academy of Sleep Medicine (AASM) diagnostic guideline recommends a comprehensive sleep evaluation followed by a clinical sleep study (polysomnography) or, for appropriate adults without complicating conditions, a properly performed home sleep apnea test. A questionnaire or smartwatch alone cannot diagnose apnea. If a home test is negative or inconclusive but concern remains, the guideline recommends polysomnography. More symptom context appears in Why Sleep Gets Worse With Age.
What distinguishes screening without symptoms from evaluating a suspected sleep problem?
What’s Interesting
Sleep apnea is a useful reminder that fixing a number is not automatically the same as changing a life outcome. In SAVE, CPAP reduced the average breathing-event rate from 29 to 3.7 per hour during use—a dramatic improvement on the sleep-study scoreboard—yet it did not reduce cardiovascular events in the randomized comparison. Limited nightly use is one plausible explanation, but the trial cannot tell us that better adherence would necessarily have changed the outcome.
What This Means in Practice
For living longer and better, apnea treatment has established value for breathing and symptoms; a lifespan benefit has not been established. The practical priority is an accurate diagnosis followed by a treatment plan you can use consistently.
- Get evaluated if you snore loudly, gasp, stop breathing during sleep or feel very sleepy in the day.
- For adults treated with PAP for obstructive sleep apnea, the AASM calls for follow-up to address difficulties and monitor treatment effectiveness and use. The sleep team can interpret those data within the prescribed plan. Four hours was a research cutoff, not a nightly dose established by these trials.
- Work with your sleep team on fit and comfort if you struggle with CPAP.
- Discuss the full set of appropriate options. Depending on your anatomy, severity and health, these may include PAP, an oral appliance, positional or surgical treatment, weight management, or tirzepatide for adults who meet its labeled indication.
- SAVE tested CPAP alongside usual cardiovascular care. It compared CPAP plus usual care with usual care alone and did not establish CPAP as a replacement for that care.
A primary care clinician can order a sleep study, and a sleep medicine specialist can adjust treatment.
Bottom Line
Severe sleep-disordered breathing is associated with higher mortality, with the clearest result in middle-aged men in one major cohort. PAP improves breathing, daytime sleepiness and sleep-related quality of life, but randomized trials have not shown cardiovascular-event prevention overall. Better outcomes among people using CPAP at least four hours a night are encouraging but nonrandomized. Tirzepatide reduces apnea severity in adults with obesity who meet its indication. Whether either treatment extends lifespan has not been shown.
A NOTE FROM LONGEVITY365
We read research, consult expert perspectives and work to make complicated health information easier to understand. What you’re reading here reflects how we’ve interpreted and organized that information. It is educational content—not personal medical advice, diagnosis or treatment guidance.
We’re not perfect, and neither is the available research. Evidence changes, new studies emerge and what’s appropriate for one person may not be appropriate for another.
Use this article as a starting point for your own research and conversations with qualified professionals. Always talk with your doctor or another trusted healthcare professional before making decisions that could affect your health, particularly if you take medications, are receiving treatment, have existing health conditions, are pregnant or have other circumstances that could affect what’s appropriate for you.
Reader Questions
A few questions to carry into the comments or your next conversation. Please leave out identifying or personal medical details.
- 01Which treatment outcome would you like explained further: fewer breathing interruptions, less daytime sleepiness, or fewer heart and blood-vessel problems?
- 02Which part of the article helped separate a normal age-related change from something worth asking about?
- 03What question would make a sleep conversation more useful than just chasing a better score?
Extra Insights & Sources
The evidence summaries and linked sources behind this article.
What We Know
- Severe sleep-disordered breathing is associated with higher mortality in cohort evidence. Supported (not causal).
- PAP improves excessive sleepiness and sleep-related quality of life. Established.
- CPAP did not reduce cardiovascular events across randomized trials overall. Supported.
- Tirzepatide reduces apnea severity and weight over 52 weeks in adults with moderate-to-severe apnea and obesity. Supported.
What We Don’t Know
- Whether consistent CPAP use extends lifespan. Unknown.
- How much of the adherence association is a treatment effect versus differences among people who use CPAP consistently. Uncertain.
- Whether tirzepatide’s effect on apnea reduces heart events or deaths. Unknown.
Detailed trial results
A hazard ratio (HR) compares how quickly deaths or other outcomes occurred over time; a risk ratio compares the proportions of people with an outcome. For either measure, 1 means no difference, above 1 indicates a higher rate or risk, and below 1 a lower rate or risk. A 95% confidence interval describes uncertainty around an estimate. These are comparisons between groups, not personal predictions.
Sleep Heart Health Study. Relative to an apnea-hypopnea index below 5, the adjusted hazard ratios for all-cause mortality were 0.93 for mild sleep-disordered breathing, 1.17 for moderate disease and 1.46 (95% confidence interval 1.14–1.86) for severe disease. For men ages 40–70 with severe disease, the adjusted hazard ratio was 2.09 (95% confidence interval 1.31–3.33). The mild and moderate estimates were not statistically clear.
Pooled trials and adherence. The 2023 individual-participant meta-analysis combined SAVE, ISAACC and RICCADSA, covering 4,186 adults with cardiovascular disease and apnea; 82.1% were men, mean age was 61.2 years and mean follow-up was 3.25 years. The randomized comparison found no difference in the first repeat major cardiac or cerebrovascular event (hazard ratio 1.01, 95% confidence interval 0.87–1.17). A statistical model comparing the treatment people actually used, while accounting for recorded differences and changes over time (a marginal structural on-treatment model), associated use of at least four hours a day with lower risk (hazard ratio 0.69, 95% confidence interval 0.52–0.92). The modeling addresses some measured differences but does not restore random assignment by adherence.
Detailed outcomes from the SAVE trial described above:
- Average CPAP use: 3.3 hours a night.
- Cardiovascular events: 17.0% with CPAP vs 15.4% without (HR 1.10), no significant difference.
- Other outcomes: the trial reported that CPAP significantly cut snoring and daytime sleepiness, and that quality of life and mood improved.
Updated trial synthesis. The 2026 meta-analysis included 11 randomized trials and 6,139 participants. CPAP did not reduce major cardiovascular events overall (risk ratio 1.00, 95% confidence interval 0.87–1.14) or the reported secondary cardiovascular outcomes. Study-level subgroups with at least four hours of nightly use favored CPAP for major events, but these adherence-defined groups were not randomized.
SURMOUNT-OSA. Trial 1 randomized 234 people not using PAP; trial 2 randomized 235 people using PAP. At 52 weeks, the placebo-adjusted reductions were 20.0 breathing events per hour (95% confidence interval 14.2–25.8) and 23.8 (95% confidence interval 17.9–29.6), respectively. The label notes that trial 2 suspended PAP for seven days before the outcome assessment and did not test when discontinuing PAP would be appropriate.
Source Materials
- Punjabi et al., 2009 — sleep-disordered breathing and mortality. Prospective Sleep Heart Health Study analysis of 6,441 adults age 40 and older followed for an average 8.2 years; severe disease was associated with higher all-cause mortality, especially among men ages 40–70. Observational design, subgroup uncertainty and disclosed device-industry relationships prevent causal interpretation.
- McEvoy et al., 2016 — SAVE randomized trial. Randomized 2,717 adults ages 45–75 with moderate-to-severe apnea and established coronary or cerebrovascular disease; over 3.7 years, CPAP did not reduce the composite cardiovascular outcome but improved several symptoms and patient-reported outcomes. Average use was 3.3 hours nightly, and participants were mostly minimally sleepy men, limiting generalizability.
- Sánchez-de-la-Torre et al., 2023 — CPAP adherence and recurrent cardiovascular events. Individual-participant meta-analysis of three randomized trials, 4,186 adults and mean 3.25-year follow-up; the randomized comparison was null, while an on-treatment model associated use of at least four hours with lower risk. Adherence itself was not randomized; several authors disclosed ResMed relationships.
- Almuzainy et al., 2026 — updated CPAP cardiovascular trial synthesis. Meta-analysis of 11 randomized trials and 6,139 participants found no overall reduction in major cardiovascular events or mortality; adherence-defined subgroups favored CPAP. The subgroup comparison is vulnerable to adherence bias and does not establish four hours as a causal threshold; authors declared no conflict.
- Patil et al., 2019 — AASM PAP treatment guideline. Evidence-based guideline recommending PAP for adults with excessive sleepiness and suggesting it for impaired sleep-related quality of life or comorbid hypertension, with follow-up and adherence support. It does not claim that PAP extends life.
- Kapur et al., 2017 — AASM diagnostic-testing guideline. Recommends comprehensive evaluation plus polysomnography or a technically adequate home test in appropriate symptomatic adults; questionnaires alone do not diagnose apnea. Home testing is not suitable for every patient, and a negative or inconclusive home test may require polysomnography.
- USPSTF, 2022 — screening for obstructive sleep apnea. Found insufficient evidence for population screening among adults without recognized symptoms. The statement does not apply to diagnostic evaluation of people with symptoms or concerns.
- Malhotra et al., 2024 — SURMOUNT-OSA. Two 52-week randomized trials totaling 469 adults with moderate-to-severe apnea, obesity and no type 2 diabetes; tirzepatide improved apnea severity, weight and related intermediate measures versus placebo. Eli Lilly funded the trials, company employees were among the authors, and cardiovascular events and mortality were not tested outcomes.
- FDA, 2024 approval announcement and January 2026 prescribing information. Establish the current US indication for tirzepatide in moderate-to-severe apnea among adults with obesity, alongside diet and physical activity, and provide contraindications, warnings and dosing. Regulatory approval is not evidence of longer life.
Leave a Reply